Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Dulaglutide (Trulicity) peptide icon, one bubble per amino acidDulaglutide (Trulicity)31 residuesHGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Dulaglutide (Trulicity)

Beginner tier: 0.75 mg, weekly · FDA label

Weight LossFDA Approved
~5 days half-life·Injection

Also known as: Trulicity, LY2189265

A 12% reduction in heart attacks, strokes, and cardiovascular death over 5.4 years. That's what the REWIND trial landed on in 9,901 adults with type 2 diabetes. Dulaglutide (Trulicity) is Eli Lilly's once-weekly GLP-1 receptor agonist, delivered through a pre-filled pen that needs zero reconstitution and zero needle attachment. HbA1c drops range from 1.0 to 1.87% across the AWARD trial program, with modest weight loss of 1.5 to 4.6 kg depending on dose. It won't match semaglutide or tirzepatide for weight loss. But for T2D patients who want proven cardiovascular protection in the simplest delivery format available, dulaglutide still holds ground.

What Is Dulaglutide (Trulicity)?

A 12% cut in cardiovascular death, heart attack, and stroke. That's what 9,901 people in the REWIND trial got over a median 5.4 years of once-weekly dulaglutide [1]. About 69% of those participants had no prior cardiovascular disease. That makes it the first GLP-1 receptor agonist to show benefit in a primary prevention population.

Dulaglutide (brand name Trulicity, CAS 923950-08-7) is a fusion protein built by Eli Lilly. Two GLP-1 analog sequences connect to a modified human IgG4 Fc domain, forming a homodimer of roughly 63 kDa. That Fc domain slows renal clearance enough to push the half-life to about 5 days. One injection per week, delivered through a pre-filled pen with a hidden needle.

On the blood sugar side, HbA1c reductions run 1.0 to 1.87% depending on dose. The AWARD-11 trial [2] tested the higher 3.0 mg and 4.5 mg strengths in 3,623 adults; the top dose pulled HbA1c down 1.87% and weight down 4.6 kg at 36 weeks. Most community users stay at 0.75 to 1.5 mg. GI tolerability drops off sharply above that.

The honest comparison: semaglutide beats dulaglutide for both HbA1c reduction and weight loss at equivalent weekly doses (SUSTAIN-7)[3]. Tirzepatide pushes even further ahead. Dulaglutide's real selling points are the pen's simplicity (no reconstitution, no needle attachment, no dose dialing) and a mature safety profile backed by 10+ years of post-marketing data. For T2D patients who prioritize convenience and have solid cardiovascular reasons to be on a GLP-1, it fills a clear role.

How Dulaglutide (Trulicity) Works

Dulaglutide binds GLP-1 receptors on pancreatic beta cells. That triggers adenylyl cyclase, raising intracellular cAMP. The downstream result is glucose-dependent insulin secretion, meaning insulin release only ramps up when blood sugar is raised. This glucose-dependence is why hypoglycemia risk with dulaglutide alone stays low.

The molecule also suppresses glucagon from alpha cells after meals. Glucagon normally tells the liver to dump glucose into the bloodstream; blocking that postprandial spike tightens glucose control in a way that insulin alone can't match.

Gastric emptying slows down too. Food moves through the stomach more gradually, blunting the postprandial glucose surge that spikes blood sugar 30 to 90 minutes after eating. This same mechanism is why nausea is the most common side effect during dose titration.

The appetite piece involves hypothalamic satiety centers. GLP-1 receptors in the brain reduce hunger signaling, which drives the modest weight loss seen in the AWARD trials.

What makes dulaglutide last a full week comes down to its structure. The GLP-1 analog portion is 90% homologous to native GLP-1, but native GLP-1 gets destroyed by DPP-4 enzymes within minutes. Dulaglutide's modified IgG4 Fc domain (forming a ~63 kDa homodimer) protects the active portion from enzymatic breakdown and reduces renal clearance. The resulting half-life sits at approximately 120 hours. Steady-state plasma levels are reached within 2 to 3 weeks of weekly dosing (Geiser et al., Clin Pharmacokinet 2016)[4]. Subcutaneous bioavailability is dose-dependent: roughly 65% at the 0.75 mg dose and 47% at 1.5 mg.

Dulaglutide (Trulicity) Benefits

  • Dulaglutide benefits center on reliable glycemic control, cardiovascular protection, and the practical convenience of a pre-filled weekly pen.
  • HbA1c reductions of 1.0 to 1.87% across the AWARD trial program (AWARD-11, n=3,623)[2]. The 4.5 mg dose hit the upper end at 36 weeks.
  • Cardiovascular protection over 5.4 years in REWIND (n=9,901)[1]. The hazard ratio for MACE came in at 0.88 (95% CI 0.79 to 0.99). Roughly 69% of participants had no prior cardiovascular disease, making this primary prevention data.
  • Renal protection confirmed in post-hoc analysis. Dulaglutide slowed eGFR decline and reduced new macroalbuminuria onset [5]. AWARD-7 specifically studied patients with moderate-to-severe chronic kidney disease.
  • The simplest GLP-1 pen on the market. No reconstitution, no needle attachment, no dose dialing. Remove the cap, press against skin, hold the button. Community users consistently rank it the easiest injectable to start with.
  • Modest but consistent weight loss of 1.5 to 4.6 kg depending on dose. This is notable because dulaglutide often gets prescribed alongside insulin therapy that typically causes weight gain.
  • Lower GI burden at starting doses than semaglutide. Community data across Drugs.com (n=980) puts nausea at roughly 22% for dulaglutide 0.75 mg versus approximately 44% for Ozempic at comparable initiation doses.

Dulaglutide (Trulicity): Science vs Community Consensus

Aligned
Scientific Evidence
Strong
Based on 8 key studies·FDA-approved

FDA-approved once-weekly GLP-1 RA for T2D.

Dosing studied: 0.75–4.5 mg SC once weekly; titrate every ≥4 weeks
Read the evidence (key study, limitations)

Strong evidence for HbA1c reduction (1.0–1.87% across AWARD program) and cardiovascular risk reduction (REWIND: HR 0.88 vs placebo over 5.4 years). Modest weight loss (1.5–4.6 kg dose-dependent). Strong renal protective signal in CKD subgroups (AWARD-7; REWIND post-hoc)[5].

Key Study

REWIND trial (PMID 31189511): n=9,901, median 5.4-year follow-up, MACE HR 0.88 (95% CI 0.79–0.99)

Limitations

Head-to-head data vs semaglutide (SUSTAIN-7, PMID 29397376) shows semaglutide superior for HbA1c reduction and weight loss at equivalent weekly doses. No approved indication for obesity without T2D. 4.5 mg dose approved 2020; long-term outcomes at higher doses not yet established beyond AWARD-11.

Community Experience
Strong
3.0/5
Based on Drugs.com n=980 (rating 5.3/10)

Well-regarded for T2D management with the convenience of a no-reconstitution pen.

Community dosing: Most community users stay at 0.75–1.5 mg/week; higher doses associated with GI dropout
Read the reports (what users report 5, common issues 5)

Users frequently switch to semaglutide or tirzepatide when more weight loss is desired. GI side effects at 3–4.5 mg strongly polarize ratings.

What users report (5)
  • Easiest GLP-1 pen to use: no needle attachment or reconstitution
  • Reliable HbA1c and fasting glucose improvement within 4–8 weeks
  • Appetite suppression noticeable at 1.5 mg for most users
  • Well-tolerated at 0.75–1.5 mg vs Ozempic at low doses (nausea ~22% vs ~44%)
  • Lilly savings card brings cost to $25/month for commercially insured patients
Common issues (5)
  • Significant nausea/vomiting at 3–4.5 mg causes high dropout at higher doses
  • Weight loss modest vs semaglutide and tirzepatide: major reason for switching
  • Pen auto-injection mechanism occasionally fails or feels abrupt
  • Some users report injection-site bruising or stinging more than with alternatives
  • Insurance coverage disputes and prior-auth requirements common
Science & Community Aligned

Community protocols closely mirror the FDA label. Off-label weight-loss use is minimal: most users are prescribed for T2D. The primary community divergence is dose ceiling: many users stop at 1.5 mg due to GI tolerability while FDA supports titration to 4.5 mg.

Dulaglutide (Trulicity) Dosage Guide

FDA LabelTrulicity (dulaglutide) FDA Prescribing Information (2022) (n=3,623 (AWARD-11))Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner0.75 mgWeekly
Moderate1.5 mgWeekly
Aggressive4.5 mgWeekly
Note:

Trulicity ships ready to inject. No vials, no bacteriostatic water, no syringe math. Each pen contains a single fixed dose with an integrated needle. Store pens in the fridge at 2 to 8 degrees Celsius. If you need to travel, they're stable at room temperature (up to 30 degrees Celsius) for 14 days. Don't freeze them.

Before injection, let a cold pen sit out for about 30 minutes. Cold pens are the number one cause of activation failures and injection site stinging. Look through the pen window to confirm the solution is clear and colorless. Cloudy or discolored liquid means toss it.

Four dose strengths exist: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. Each pen is a single strength with no volume to measure or calculate.

Start at 0.75 mg weekly. If blood sugar targets aren't met after four weeks, step up to 1.5 mg. Most community users stay at 1.5 mg long-term; that's the sweet spot between efficacy and GI tolerability for the majority. Don't rush dose escalation. GI side effects spike with every step up, and giving your gut 4 weeks to adapt makes the difference between tolerating the drug and quitting it.

Cycling

No scheduled off period.

Dulaglutide is used continuously as a chronic therapy for type 2 diabetes. No cycling is required or recommended. Discontinuation should be discussed with a prescribing physician, as glycemic control and cardiovascular benefits depend on ongoing use.

Calculate your Dulaglutide (Trulicity) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Dulaglutide (Trulicity) Protocols by Goal

beginnerFDA LabelOngoing (chronic therapy: no defined end date)
Initiation
Wk 1–4
0.75 mg · Once weekly · Subcutaneous (pre-filled pen)
Standard maintenance
Wk 5+
1.5 mg · Once weekly · Subcutaneous (pre-filled pen)

Expected: HbA1c reduction of 1.0–1.4% from baseline; fasting glucose improvement within 2–4 weeks; weight loss of 1.5–3 kg

Monitor: Check HbA1c at 3 months. Monitor eGFR and blood pressure annually. Self-monitor BG per clinician guidance.

How to Inject Dulaglutide (Trulicity)

  1. 1
    Remove one Trulicity pen from the refrigerator

    Let it sit at room temperature for about 30 minutes. Cold pens sting more and are harder to activate.

  2. 2
    Inspect the pen window

    The solution should be clear and colorless. Do not use if cloudy, discolored, or if particles are floating in it.

  3. 3
    Choose your injection site: abdomen, thigh, or upper arm

    Rotate to a different area each week. Clean the site with an alcohol swab and let it dry.

  4. 4
    Pull the gray base cap straight off the pen

    This unlocks the device.

  5. 5
    Place the pen base flat against your skin

    Press and hold the green injection button. You'll hear a first click (the needle inserts). Keep holding for about 10 seconds until you hear a second click (injection complete).

  6. 6
    Lift the pen away

    Check the window to confirm the gray plunger has moved. If it hasn't, the full dose may not have been delivered.

  7. 7
    Dispose of the pen in a sharps container

    Each pen is single-use. Never reuse or share pens.

Timing: inject on the same day each week. Any time of day works, with or without food. If you need to change your injection day, the last dose must have been at least 3 days prior.

No syringe units to calculate. No reconstitution math. The pen delivers a fixed dose. That's one of dulaglutide's biggest practical advantages over vial-and-syringe GLP-1 options.

Dulaglutide (Trulicity) Stacking Protocols

Works With

Metformin

Standard-of-care first-line T2D combination. Complementary mechanisms: metformin reduces hepatic glucose output; dulaglutide increases glucose-dependent insulin secretion and suppresses glucagon. No pharmacokinetic interaction.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)

Additive glycemic and cardiovascular/renal benefits. SGLT2 inhibitors provide independent heart failure and renal protection not covered by GLP-1 agonists. Combination endorsed in ADA/EASD guidelines for T2D patients with HFrEF or CKD.

Standard approved doses of each agent; no dose adjustment required

Basal insulin (glargine, degludec)

Used for T2D patients not meeting HbA1c targets on oral agents + GLP-1 RA alone. Dulaglutide reduces required insulin dose by suppressing postprandial glucagon and slowing gastric emptying.

Titrate insulin to fasting BG target; monitor for hypoglycemia: insulin dose reduction often needed when adding dulaglutide

DPP-4 inhibitors (sitagliptin, saxagliptin)

Occasionally combined in clinical practice. Incremental HbA1c benefit is small (~0.2–0.4%) since DPP-4 inhibitors upregulate endogenous GLP-1, partially overlapping with dulaglutide's mechanism. Not guideline-preferred over escalating dulaglutide dose.

Avoid

Semaglutide (Ozempic, Wegovy, Rybelsus)

Duplicate GLP-1 receptor agonist mechanism. Combining two GLP-1 RAs provides no additional efficacy and substantially increases GI side effects. Switch is appropriate; concurrent use is not.

Do not combine
Liraglutide (Victoza, Saxenda)

Duplicate GLP-1 receptor agonist mechanism. Same clinical rationale as semaglutide: no additive benefit, amplified GI adverse effects.

Do not combine
Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is a dual GIP/GLP-1 agonist: the GLP-1 component duplicates dulaglutide's mechanism. Concurrent use not studied; expected to amplify GI side effects without additional therapeutic benefit.

Do not combine
Sulfonylureas (glipizide, glimepiride, glyburide)

Additive hypoglycemia risk, especially in elderly or renally impaired patients. If combination required, reduce sulfonylurea dose and monitor closely.

Estimated Cost

Brand Price
~$987/month retail (4-pen, 28-day supply; all dose strengths same price without insurance). Lilly savings card: $25/month for commercially insured patients (max $150/fill, annual cap $1,950; not valid for Medicare/Medicaid/TRICARE). Most Favored Nation pricing agreement (Nov 2025): $389/month: implementation variable.
Generic / Research
No generic available. Patent protection expected until ~2031; biosimilar potential entry ~2033–2034. Some reports suggest a generic could emerge as early as 2027: unconfirmed.
Compounded
Not available. Dulaglutide is not on the FDA drug shortage list and is patent-protected as a large-molecule biologic. No legitimate compounded dulaglutide formulation exists.

Pricing updated 2026-04-09

Dulaglutide (Trulicity) Side Effects

The FDA label carries a boxed warning for medullary thyroid carcinoma. In rodent studies, GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors. Whether this applies to humans remains unknown after more than a decade of post-marketing surveillance. No confirmed cases in humans have been attributed to GLP-1 receptor agonists. Still, dulaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Report any neck mass, hoarseness, or difficulty swallowing immediately.

Pancreatitis is the second serious concern. Cases are rare but documented across the GLP-1 class. Severe persistent abdominal pain radiating to the back warrants stopping the drug and getting amylase and lipase checked. Do not restart dulaglutide after confirmed pancreatitis.

Gastrointestinal side effects are the daily reality for most patients during titration. Nausea hits 8 to 21% depending on dose. Diarrhea runs 8 to 12%. Vomiting, abdominal pain, and decreased appetite round out the GI profile. These effects are dose-dependent and usually peak during the first four weeks at each dose level. Most people tolerate 0.75 mg and 1.5 mg without major issues.

The jump to 3.0 mg and 4.5 mg is where things get harder. In AWARD-11 data, nausea resurgence at 3.0 mg hit 20 to 35% of participants during the titration window. Vomiting climbed to 10 to 15%. Community dropout at the higher doses is high specifically because of renewed GI symptoms.

Community reviews on Drugs.com (n=980, average rating 5.3/10) and WebMD (n=271, average 3.3/5) confirm this pattern. Users at 0.75 to 1.5 mg report satisfaction with glycemic control and manageable side effects. Users who escalated to 3.0 mg or 4.5 mg report renewed nausea that sometimes prompted switching to a different GLP-1.

Hypoglycemia risk with dulaglutide alone is low because insulin secretion is glucose-dependent. That changes when insulin or sulfonylureas enter the picture. Dose reductions of the concurrent insulin or sulfonylurea are typically needed. Elderly patients and those with renal impairment face higher risk in combination therapy.

Injection site reactions (bruising, stinging, induration) show up more in community reports than in clinical trial data. The pen's auto-injection mechanism can feel abrupt. Letting the pen warm to room temperature for 30 minutes before use helps. Rotating injection sites across abdomen, thigh, and upper arm on a weekly cycle reduces recurrence.

Slowed gastric emptying can delay absorption of oral medications taken around the same time. Warfarin and levothyroxine absorption may shift enough to warrant closer monitoring of INR and thyroid levels during initiation or dose changes.

Pregnancy is a hard stop. Animal data shows potential fetal harm. The FDA label recommends discontinuing at least 2 months before planned pregnancy. The 5-day half-life means meaningful drug levels persist for weeks after the last injection.

When to contact a physician: persistent severe abdominal pain, neck mass or hoarseness, signs of anaphylaxis (difficulty breathing, swelling of face or throat), or repeated hypoglycemic episodes when used with insulin.

Common Issues & Solutions

GI side effects at 0.75 mg: Typically transient (peak weeks 1–4, resolve by week 8). Eat smaller meals, avoid high-fat/high-sugar foods, and consider taking the weekly injection at bedtime to sleep through peak side effects.

GI worsening at dose escalation: Hold the current dose for an additional 4 weeks before escalating. If intolerable at 3 mg or 4.5 mg after 8 weeks, return to the previous tolerated dose rather than discontinuing entirely.

Pen activation failure (no second click or incomplete injection): Press pen base firmly flat against skin, hold button down for a full 10 seconds, and confirm the gray plunger has moved in the pen window. Cold pens from the refrigerator should warm to room temperature for 30 minutes before use.

Inadequate HbA1c response at 1.5 mg after 3 months: Reassess diet, physical activity, and adherence first. If optimization fails, escalate to 3.0 mg per FDA titration schedule or add metformin/SGLT2 inhibitor if not already in combination.

Injection site reactions (bruising, stinging, induration): Rotate injection sites systematically across abdomen, thigh, and upper arm on a weekly cycle. Avoid reusing the same site within 2 weeks.

Ask AI about this page

Ask AI for a second opinion on Dulaglutide (Trulicity) dosing and side effects

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • History of serious hypersensitivity reaction to dulaglutide or any product components
  • History of pancreatitis: use with caution; discontinue if pancreatitis is suspected
  • Pregnancy or breastfeeding: may cause fetal harm based on animal data; discontinue at least 2 months before planned pregnancy due to long washout
  • Severe gastrointestinal disease including gastroparesis
  • Type 1 diabetes or diabetic ketoacidosis: not indicated for these conditions

Drug Interactions

  • Insulin and sulfonylureas: increased risk of hypoglycemia; dose reduction of insulin or sulfonylurea may be needed
  • Oral medications: slowed gastric emptying may delay absorption of concomitant oral drugs
  • Warfarin: monitor INR more frequently when initiating or changing dulaglutide dose
  • Oral contraceptives: no clinically meaningful interaction observed, but consider potential delayed absorption
  • Levothyroxine: monitor thyroid levels as GI transit changes may alter absorption
  • Duplicate GLP-1 receptor agonist mechanism. Combining two GLP-1 RAs provides no additional efficacy and substantially increases GI side effects. Switch is appropriate; concurrent use is not.
  • Duplicate GLP-1 receptor agonist mechanism. Same clinical rationale as semaglutide: no additive benefit, amplified GI adverse effects.
  • Tirzepatide is a dual GIP/GLP-1 agonist: the GLP-1 component duplicates dulaglutide's mechanism. Concurrent use not studied; expected to amplify GI side effects without additional therapeutic benefit.
  • Oral contraceptives and oral hormonal therapies: the Trulicity label calls for no backup contraception. At 1.5 mg, dulaglutide did not affect absorption of the tested oral drugs to a clinically relevant degree (section 12.3). Those included the contraceptive hormones norelgestromin and ethinyl estradiol (Figure 2). Data at 3 mg and 4.5 mg are limited (section 7.1)

Product Quality

Recommended Monitoring

TestWhenTarget
HbA1cEvery 3 months until at goal, then every 6 months<7.0% for most adults with T2D per ADA 2024 guidelines; individualize per patient risk
Fasting plasma glucose / CGMOngoing self-monitoring per clinician recommendation80–130 mg/dL fasting (ADA 2024)
eGFR (estimated glomerular filtration rate)Annually; more frequently if eGFR <60 mL/min/1.73m²>60 mL/min/1.73m² (Stage 3+ CKD: monitor every 3–6 months)
UACR (urine albumin-to-creatinine ratio)Annually<30 mg/g (normal); 30–300 mg/g = microalbuminuria; >300 mg/g = macroalbuminuria
Lipid panelAnnuallyLDL <70 mg/dL for patients with established CVD
Thyroid palpation / TSH if symptomaticAt initiation; repeat only if symptoms arise (neck mass, dysphagia, hoarseness, dyspnea)Not listed
Amylase / lipaseOnly if persistent severe abdominal pain: not routine monitoringNot listed
Blood pressure and body weightEach clinical visitNot listed
HbA1c

Primary efficacy marker for glycemic control; guides dose escalation decisions

Fasting plasma glucose / CGM

Real-time glycemic feedback; detect hypoglycemia if on concurrent insulin or sulfonylurea

eGFR (estimated glomerular filtration rate)

Dulaglutide has renal protective effects documented in REWIND post-hoc; no dose adjustment needed but monitor progression

UACR (urine albumin-to-creatinine ratio)

Tracks renal protection benefit: dulaglutide reduces new macroalbuminuria onset (REWIND renal post-hoc, PMID 37343574)

Lipid panel

GLP-1 RAs have modest favorable effects on lipids; monitor cardiovascular risk markers in high-CVD-risk population

Thyroid palpation / TSH if symptomatic

Boxed warning: risk of medullary thyroid carcinoma in rodent studies; clinical risk in humans not established but warrants symptom vigilance

Amylase / lipase

Rare pancreatitis association with GLP-1 RAs; lab evaluation only if clinical suspicion

Blood pressure and body weight

GLP-1 RAs associated with modest BP reduction; weight tracks therapeutic response and metabolic benefit

Dulaglutide (Trulicity) Before and After

Weeks 1-4
0.75mg

Starting dose. GI side effects (nausea, diarrhea) are most common during this period and typically mild. Early blood sugar improvements begin. HbA1c reduction of approximately 0.5-0.7% expected. Appetite changes may start.

Weeks 5-8
1.5mg

First dose increase if glycemic targets are not met. GI effects often lessen as the body adjusts. HbA1c reductions of approximately 1.0-1.2% from baseline. Mild weight loss of 1-2 kg may occur.

Weeks 9-16
3.0mg if needed

Higher dose option available since AWARD-11. Further HbA1c reduction (up to 1.5% from baseline). Weight loss becomes more apparent. Steady-state drug levels are well established by this point.

Weeks 17-26
up to 4.5mg

Maximum dose. AWARD-11 showed HbA1c reductions up to 1.87% and weight loss of 4.6 kg at 36 weeks with 4.5mg. Fasting glucose and postprandial glucose control optimize. GI side effects generally resolved.

Week 26+

Long-term maintenance. REWIND trial showed sustained cardiovascular protection over 5.4 years of use. HbA1c and weight benefits are maintained while on therapy. Renal protective effects observed with prolonged use.

What to Expect

Weeks 1 through 4 (0.75 mg): Steady-state builds over the first 2 to 3 weeks given the 5-day half-life. Fasting glucose starts dropping. HbA1c trends downward, with roughly 0.5 to 0.7% reduction expected by the end of this phase. Appetite changes often show up within the first 1 to 2 weeks. Nausea hits 8 to 14% of users during this stretch; diarrhea runs 8 to 12%. Most people handle 0.75 mg without major issues. Community users frequently mention earlier satiety at meals and occasional injection site bruising.

Weeks 5 through 12 (1.5 mg): This is where most community users stay long-term. HbA1c reduction reaches 1.0 to 1.4% from baseline at 26 weeks (AWARD-6 data, vs liraglutide). Weight loss of 1.5 to 3 kg becomes visible. GI side effects from the dose step usually fade as the gut adapts. Nausea drops to about 5 to 8%. Some users develop constipation at this stage. Blood sugar improvements are consistent on CGM and fingerstick monitoring alike.

Weeks 13 through 24 (3.0 mg if escalated): Incremental HbA1c drop of about 0.4 to 0.5% beyond the 1.5 mg result. Weight loss increases to roughly 3.5 kg. Nausea comes back hard during dose escalation (20 to 35% of users), with vomiting in 10 to 15% and diarrhea in 15 to 20%. Community dropout at this dose is high. Those who push through report better postprandial glucose control. This is the dose where many patients start comparing to Ozempic or Mounjaro.

Weeks 25 and beyond (4.5 mg maximum): AWARD-11 [2] tracked peak HbA1c reduction of 1.87% and weight loss of 4.6 kg at 36 weeks. Fasting and postprandial glucose reach their best numbers here. GI effects are generally resolving by week 36. Community reports at this dose are limited because GI tolerability keeps most people at lower doses. Those who reach 4.5 mg tend to report the strongest metabolic outcomes.

Year 1 and beyond: REWIND followed participants for a median of 5.4 years. Cardiovascular protection held (HR 0.88 for MACE) across the full follow-up. HbA1c and weight benefits stay stable with continued use. Renal protection builds over years of treatment (slowed eGFR decline, reduced new macroalbuminuria per)[5]. Some long-term users switch to semaglutide or tirzepatide for greater weight loss. The Lilly savings card at $25 per month for commercially insured patients keeps adherence high for those who stay on.

Detailed Timeline: Science vs Community

Weeks 1–4 (0.75 mg)
Science

Steady-state achieved ~2–3 weeks (5-day half-life). Fasting glucose begins declining. HbA1c trend downward (~0.5–0.7% reduction expected by end of phase). Mild appetite suppression onset.

Community

Most users tolerate 0.75 mg well. Nausea reported but typically mild. Many note reduced appetite and earlier satiety within 1–2 weeks. Injection site bruising occasionally reported.

Weeks 5–12 (1.5 mg)
Science

HbA1c reduction of ~1.0–1.4% from baseline at 26 weeks (AWARD-6, vs liraglutide). Weight loss of 1.5–3 kg. GI side effects diminish as GI adaptation progresses.

Community

Most users plateau here for long-term use: balances efficacy and tolerability. Weight loss visible and appreciated. GI symptoms improved vs initiation phase. Consistent blood sugar improvement on CGM and self-monitoring.

Weeks 13–24 (3.0 mg if escalated)
Science

Incremental HbA1c reduction of ~0.4–0.5% over 1.5 mg. Weight loss increases to ~3.5 kg. GI side effects increase with dose escalation but typically transient.

Community

High dropout at 3 mg due to renewed nausea. Users who tolerate this dose report greater weight loss and better postprandial glucose control. This is where many patients begin comparing to Ozempic or Mounjaro.

Weeks 25+ (4.5 mg maximum)
Science

HbA1c reduction up to 1.87% and weight loss up to 4.6 kg at 36 weeks (AWARD-11, PMID 33397768). Maximum fasting and postprandial glucose control. GI effects generally resolving by week 36.

Community

Few community reports at this dose: GI tolerability limits real-world uptake. Those who reach 4.5 mg report best overall metabolic outcomes. Common comparison point: tirzepatide noted as more effective for weight loss by community.

Long-term (Year 1+)
Science

REWIND: sustained MACE reduction (HR 0.88) over 5.4-year median follow-up. Sustained HbA1c and weight benefit during continued use. Renal protective effect documented (slowed eGFR decline, reduced new macroalbuminuria onset per PMID 37343574).

Community

Long-term users report stable glycemic control and weight maintenance. Some community attrition as patients switch to semaglutide or tirzepatide for greater weight loss. Lilly savings card significantly improves adherence at $25/month for commercially insured.

Pharmacokinetics

Half-Life
120h
Bioavailability
SC: ~47-65% (dose-dependent; 65% at 0.75mg, 47% at 1.5mg)
Tmax
~48 hours (range 24-72h)
Data Confidence
high

Source: FDA Prescribing Information (Trulicity), Section 12.3; Geiser et al. Clin Pharmacokinet 2016 PMID:26507721

Pharmacokinetics: Active Dose Over Time

t½ = ~5 days (120 hours)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
31
Sequence
HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 923950-08-7

Who Should Consider Dulaglutide (Trulicity)

  • Adults with type 2 diabetes requiring improved glycemic control
  • Type 2 diabetics at elevated risk for major adverse cardiovascular events
  • Adults with type 2 diabetes and established cardiovascular disease
  • Patients seeking a once-weekly injectable with no reconstitution needed
  • Type 2 diabetics with moderate-to-severe chronic kidney disease (AWARD-7 data)
  • Adults who prefer a pre-filled pen over daily injectable GLP-1 therapies

Related Peptides

What Changed for Dulaglutide (Trulicity)

  1. Safety

    Corrected Oct 13, 2026: dulaglutide 1.5 mg had no clinically relevant effect on tested oral drugs; no backup contraception is advised, per the Trulicity label.

    Before: Additional contraceptive precautions recommended during initiation and dose escalation (GLP-1 class wording) After: The Trulicity label calls for no backup contraception. At 1.5 mg, the tested oral drugs (norelgestromin and ethinyl estradiol among them) were not affected to a clinically relevant degree

    What this does not mean: Dulaglutide still slows gastric emptying, so the label says to monitor narrow-margin drugs such as warfarin. Data at 3 mg and 4.5 mg are limited. The tirzepatide label does call for backup contraception.

    Source: Trulicity (dulaglutide) prescribing information (openFDA label record, SPL version 62, effective Jun 16, 2026; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations

References

  1. [1]Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]AWARD-11: Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg (AWARD-11) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]SUSTAIN-7: Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial (Lancet Diabetes Endocrinol 2018) (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  4. [4]Clinical Pharmacokinetics of Dulaglutide (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]AWARD-7: Dulaglutide and kidney function-related outcomes in type 2 diabetes: a REWIND post hoc analysis (Botros et al., Diabetes Care 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
N/A: supplied as liquid in pre-filled pen
After Reconstitution
Refrigerate at 2-8°C in original carton. May store at room temperature (up to 30°C) for up to 14 days.
Temperature
2-8°C (36-46°F); up to 30°C (86°F) for 14 days

Frequently Asked Questions

Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction. The REWIND trial (n=9,901) showed a 12% reduction in major adverse cardiovascular events over 5.4 years (PMID 31189511). It is a once-weekly GLP-1 agonist manufactured by Eli Lilly.

Start at 0.75 mg subcutaneous once weekly. After 4 weeks, increase to 1.5 mg weekly if tolerated. Maximum dose: 4.5 mg weekly. The 4.5 mg dose showed additional A1c and weight benefit in the AWARD-11 trial but with higher GI side effect rates.

Both are once-weekly GLP-1 agonists. Semaglutide produces more weight loss: SUSTAIN 7 showed semaglutide 1.0 mg outperformed dulaglutide 1.5 mg on both A1c (-1.8% vs -1.4%) and weight (-6.5 kg vs -3.0 kg). Dulaglutide has a strong CV outcomes dataset (REWIND) and a convenient prefilled autoinjector.

Nausea (21-30%), diarrhea (13-21%), vomiting (7-13%), and abdominal pain (9-12%) per the AWARD program. The FDA black box warning covers medullary thyroid carcinoma risk from preclinical rodent data. Pancreatitis and gallbladder events are rare but documented across the GLP-1 class.

The half-life of Dulaglutide (Trulicity) is ~5 days (120 hours). This determines how frequently you need to dose for consistent blood levels.